pharma · Renal Impairment · Urinary Tract Infection · SPRO
Spero Therapeutics
Spero Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SPRO. Primary therapeutic focus areas include Renal Impairment, Urinary Tract Infection, complicated urinary tra
Company details
- Status
- Public
- HQ
- 675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
- Founded
- 2013
- Employees
- 45
- Programs
- 21
- Drugs
- 9
- Patents
- 16
Quick answer
Spero Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SPRO. Primary therapeutic focus areas include Renal Impairment, Urinary Tract Infection, complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD), Mycobacterium Avium Complex. NovaPharmaNews links 21 clinical program(s), 0 drug profile(s), and 16 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (16), phase 3 (3), phase 2 (2).
Company snapshot
We are a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need.
- 21 active pipeline program(s) linked via ClinicalTrials.gov.
- 16 US patent(s) indexed to this assignee profile.
- 21 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Spero Therapeutics. Not investment advice.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 2
Momentum
Proprietary activity score for Spero Therapeutics.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Spero Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference — Phase 1
- Clinical update
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo — Phase 1
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Spero Therapeutics?
-
Is Spero Therapeutics publicly traded?
-
What drugs does Spero Therapeutics develop or market?
-
What are the latest developments for Spero Therapeutics?
-
What therapeutic areas does Spero Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.